Literature DB >> 7439523

High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite.

J L Borgna, H Rochefort.   

Abstract

The tritiated 4-hydroxytamoxifen (OHT), an active metabolite of tamoxifen found in estrogen target nuclei, was prepared in vitro and its interaction with the cytosol estrogen receptor (R) of uterus and chick oviduct was specified. OHT bound to the 8S R with the same affinity and the same kinetic parameters as estradiol (E2). Its ability to protect the E2-binding sites and to stabilize the R--DNA interaction was also similar to that of E2. We conclude that the binding characteristics in vitro of ligands on the cytosol R do not presently allow us to discriminate between agonist and antagonist ligands.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439523     DOI: 10.1016/0303-7207(80)90095-7

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  17 in total

1.  Binding site matching in rational drug design: algorithms and applications.

Authors:  Misagh Naderi; Jeffrey Mitchell Lemoine; Rajiv Gandhi Govindaraj; Omar Zade Kana; Wei Pan Feinstein; Michal Brylinski
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

2.  Ester derivatives of the mammary-tumor-inhibiting antiestrogen 2,3-bis(2-fluoro-4-hydroxyphenyl)-2,3-dimethylbutane.

Authors:  W Schwarz; R W Hartmann; J Engel; M R Schneider; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

3.  Interaction of the radiolabelled high-affinity anti-oestrogen [3H]H1285 with the cytoplasmic oestrogen receptor.

Authors:  J L Keene; F Sweet; M F Ruh; T S Ruh
Journal:  Biochem J       Date:  1984-02-01       Impact factor: 3.857

4.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Authors:  Ping Fan; Wei Yue; Ji-Ping Wang; Sarah Aiyar; Yan Li; Tae-Hyun Kim; Richard J Santen
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

5.  Physicochemical and genetic evidence for specific antiestrogen binding sites.

Authors:  J C Faye; S Jozan; G Redeuilh; E E Baulieu; F Bayard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

6.  Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.

Authors:  A Mahfoudi; E Roulet; S Dauvois; M G Parker; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

7.  Effect of the anti-oestrogen tamoxifen on the development of renal cortical necrosis induced by oestrone + vasopressin administration in rats.

Authors:  J Kocsis; G Karácsony; S Karcsú; F A László
Journal:  Br J Exp Pathol       Date:  1988-04

8.  Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody.

Authors:  A C Tate; E R DeSombre; G L Greene; E V Jensen; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

9.  High affinity binding of anti-oestrogen to the chick liver nuclear oestrogen receptor.

Authors:  C B Lazier; V C Jordan
Journal:  Biochem J       Date:  1982-08-15       Impact factor: 3.857

10.  Nuclear oestrogen receptors in rat liver. Development of assay conditions, characterization and the translocation of oestrogens in vivo.

Authors:  P Tamulevicius; E R Lax; A Müller; H Schriefers
Journal:  Biochem J       Date:  1982-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.